These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 15258356)

  • 21. The influence of oxygen supply, hemorheology and microcirculation in the heart and vascular systems.
    Cicco G; Cicco S
    Adv Exp Med Biol; 2010; 662():33-9. PubMed ID: 20204768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemorheological status of an organism with normal versus changed blood vessels].
    Gushchin AG; Murav'ev AV; Shaechkina IK; Gushchina GM
    Fiziol Cheloveka; 2001; 27(4):82-4. PubMed ID: 11573416
    [No Abstract]   [Full Text] [Related]  

  • 23. Endothelial function, fluid dynamics, hemorheology implications for clinical and preclinical vascular disease and implications for the ESCHM.
    Gori T
    Clin Hemorheol Microcirc; 2016; 64(4):521-524. PubMed ID: 27767970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemorheological, platelet and endothelial factors in essential hypertension.
    Lee AJ
    J Hum Hypertens; 2002 Aug; 16(8):529-31. PubMed ID: 12149657
    [No Abstract]   [Full Text] [Related]  

  • 25. Hemorheology and vascular endothelial cells.
    Stoltz JF; Muller S; Wang X; Dumas D; Boisseau M; Legrand S; Labrador V
    Clin Hemorheol Microcirc; 1999; 20(2):127-39. PubMed ID: 10416815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyslipidaemia versus endothelial dysfunction: which is more important in the development of vascular disease?
    Ferrannini E; Tuomilehto J
    Int J Clin Pract Suppl; 2003 Oct; (137):5-14. PubMed ID: 14649697
    [No Abstract]   [Full Text] [Related]  

  • 27. [Circulating endothelial cells: a marker of vascular lesion].
    George F; Sampol J
    Nouv Rev Fr Hematol (1978); 1993 Jun; 35(3):259-61. PubMed ID: 8337140
    [No Abstract]   [Full Text] [Related]  

  • 28. Hemorheology and hemostasis in vascular disease. A pathophysiological review.
    Angelkort B; Amann B; Lawall H
    Clin Hemorheol Microcirc; 2002; 26(3):145-54. PubMed ID: 12082246
    [No Abstract]   [Full Text] [Related]  

  • 29. Can white blood cell activation be one of the major factors that affect hemorheological parameters during and after exercise?
    Temiz A; Yalcin O; Resmi H; Baskurt OK
    Clin Hemorheol Microcirc; 2002; 26(3):189-93. PubMed ID: 12082250
    [No Abstract]   [Full Text] [Related]  

  • 30. Medical treatment of abnormal endothelial cell function.
    Messmore HL
    Semin Thromb Hemost; 1988; 14 Suppl():47-57. PubMed ID: 3057637
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanisms involved in endothelial responses to hemodynamic forces.
    Davies PF
    Atherosclerosis; 1997 Jun; 131 Suppl():S15-7. PubMed ID: 9253470
    [No Abstract]   [Full Text] [Related]  

  • 32. [The estimation of a complex of hemorheological parameters in erythrocytosis].
    Gushchin AG; Murav'ev AV; Shaechkina IK
    Fiziol Cheloveka; 2000; 26(2):111-4. PubMed ID: 10816947
    [No Abstract]   [Full Text] [Related]  

  • 33. Interrelations between clinical microcirculation and clinical haemorheology.
    Ehrly AM; Bauersachs RM
    Clin Hemorheol Microcirc; 1999; 20(1):27-30. PubMed ID: 11185680
    [No Abstract]   [Full Text] [Related]  

  • 34. Function over form: Is it time to use endothelial function to diagnose vascular diseases?
    Lohr NL
    Int J Cardiol; 2018 Jun; 260():191-192. PubMed ID: 29622438
    [No Abstract]   [Full Text] [Related]  

  • 35. New Therapies for Endothelial Dysfunction: From Basic to Applied Research.
    Dos Santos L
    Curr Pharm Des; 2020; 26(30):3631-3632. PubMed ID: 32893756
    [No Abstract]   [Full Text] [Related]  

  • 36. Endothelium and hemorheology.
    Turchetti V; Boschi L; Donati G; Borgogni G; Coppola D; Dragoni S; Bellini MA; Sicuro S; Mastronuzzi VM; Forconi S
    Clin Hemorheol Microcirc; 2004; 30(3-4):289-95. PubMed ID: 15258356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of hemorheological and endothelial factors on microcirculation.
    Turchetti V; Boschi L; Donati G; Trabalzini L; Forconi S
    Adv Exp Med Biol; 2006; 578():107-12. PubMed ID: 16927678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
    Wang S; Jiang JL; Hu CP; Zhang XJ; Yang DL; Li YJ
    Diabetes Metab Res Rev; 2007 Feb; 23(2):157-64. PubMed ID: 16770837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Asymmetric dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1(sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma.
    Vasilev V; Matrozova J; Elenkova A; Vandeva S; Kirilov G; Zacharieva S
    Exp Clin Endocrinol Diabetes; 2013 Oct; 121(9):551-5. PubMed ID: 24002898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.